ESR1 and breast neoplasm: It was previously believed that patients with tumors with ER expression levels ≥1% could derive clinical benefit from endocrine therapy [7], but recent studies have revealed that breast tumors with low ER expression (1% ≤ ER ≤ 10%) may have unique molecular and clinical characteristics compared with tumors with higher ER expression (ER > 10%) [8].